PubMed Health⌕ Search

Biomedical subjects

P Morin

Publications and source records attributed to P Morin.

At least 19 recordsLinked to original sources
PubMed1979

Conformational studies on muscular parvalbumins cooperative binding of calcium (II) to parvalbumins.

1H NMR and ORD were used to characterize the respective variations of tertiary structure and secondary structure of parvalbumins with calcium content ((Pa(O), without calcium and PaCa2 calcium saturated) and temperature. It has been observed that the tertiary structure can be lost without significant variation of the helical content. Cooperative binding of calcium to Pa(O) has been shown by NMR spectroscopy under low ionic strength conditions and at neutral pH. The present study shows that the calcium binding affinity of parvalbumin is dependent on the tertiary structure. Calcium binding and calcium release functions of parvalbumins in the muscle may be controlled by their tertiary structure.

Animals↗
PubMed1979

Effect of human chorionic gonadotrophin on phagocytic activity and proliferative capacity of rat peritoneal macrophages in culture.

Human chorionic gonadotrophic hormone (hCG) decreased phagocytosis of rat peritoneal macrophages in culture and also inhibited their capacity to be stimulated by an inflammatory exudate. Both effects were related to the concentration used. These experimental results suggest that elevated levels of hCG may play a role in the prevention of the rejection of the foetal allograft by the maternal host.

Animals↗
PubMed1978

[Hysteroplasty for septate uterus by cleavage and mobilisation of the septum (author's transl)].

A new technique of hysteroplasty is proposed for the septate uterus. The uterine incision is anterior medline, leaving the posterior wall of the uterus untouched. The septum is split into two hemi-septa which are increased in such a way as to obtain two pediculated flaps, covered by endometrium. Anterior and posterior distribution of the flaps makes it possible to recreate a spacious single cavity.

Female↗
PubMed1978

[Non resectable colonic cancer. Results from a test of chemotherapy with simultaneous prescription of VM26, methyl-CCNU and 5 fluoro-uracile (author's transl)].

Thirty nine patients with non resectable colonic carcinoma entered into a phase II combination chemotherapy trial. The patients were treated with a sequential cyclic combination of 3 drugs: VM 26 (60 mg/m2), methyl-C.C.N.U. (120 mg/m2) and 5 fluoro-uracile. Seventeen patients out of 39 (43.6%) are considered as good responders. The median survival time of the overall of this group is 12.6 months; it is of 15,6 months for good responders and of 7 months for non responders. The simultaneous application of B.C.G. do not change neither the level of responses nor the median of survival time. The good tolerance of this protocol let us to propose this combination as an adjuvant treatment for patients surgically treated for a Dukes'C colonic cancer.

Adult↗
PubMed1978

[Non resectable squamous cell carcinoma of the bronchus. Study of the immunological status as prognosis factor and attempt at immunorestoration with B.C.G. (author's transl)].

Sixty-six patients with bronchus non resectable squamous cell carcinoma (stage III and 14) entered into a protocol of chemotherapy depending upon their initial immunological status. These patients with (+) skin tests to recall antigens were allocated to a chemotherapy programme; patients with initially (-) skin tests were submitted to a protocol of immunorestauration with B.C.G. After three weeks of B.C.G. applications on scarifications 17 patients out of 31 presented with (+) skin tests and were considered as immunocompetent patients. All the patients then were submitted to chemotherapy protocol. The comparison of different median of survival have demonstrated that immune status appears as the more fundamental prognosis factor; the B.C.G. is able to transitory restore the immunity of the patients without any modification of the tumour progress. The median of survival of patients with initially (+) skin tests was ten months, and only two months for patients with (-) skin tests. The median of survival of patients whom immunity was restored with B.C.G. was nine months. The results of this trial let us to propose new strategy for treatment of these patients.

Adult↗
PubMed1978

[Various metabolic or toxic effects which can result from short term ingestion of sulfurous acid by the rat].

The work reported below was conducted for the purpose of evaluating the toxicity of two levels of potassium metabisulfite on various aspects of metabolism in adult rats. It appears that the two doses do not disturb the activity of acid plasmatic phosphatase. The increase of the pyruvic acid o blood caused for the higher level of sulfite (50 mg/kg/day) is considerably increased for absorption of a diet containing 67% of sugar, and considerably decreased by injection the day before the dosage of 200 microgram thiamine. The highest level (50 mg/kg/day) increased the urinary calcium however same larger quantities of sulfite did not cause any augmentation of fecal calcium. The "creatinine clearance" is not modified, the seric transaminases (G.O.T.-G.P.T.) are not disturbed, moreover, hematologic controls during the five months of experimentation did not show any perturbation.

Acid Phosphatase↗
PubMed1977

Treatment of malignant gliomas and brain metastases in adults using a combination of adriamycine, VM 26, and CCNU. Results of a type II trial.

Forty-three patients with inoperable and/or recurring malignant gliomas and 30 patients with multiple recurring brain metastases were treated with a combination of adriamycine (45 mg/m 2 and 4-dimethyl-epipodophyllotoxin D-thenylidene (VM 26) (60 mg/m 2 for 2 days) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea (CCNU) (60 mg/m 2 for 2 days). These cycles of treatment were repeated as soon as the hematologic restoration was complete. The treatment was well-tolerated and the clinical condition of 31 out of 43 glioblastoma patients improved during the 2 months after the beginning of the treatment. Six out of eight patients with breast cancer metastases, one out of 13 with bronchial cancer metastases, and three out of nine with other types of cancer metastases also benefitted from the treatment. Examination of the results reveals the following characteristics: 1. A low degree of efficiency of this combination in the treatment of brain metastases, except for breast cancer metastases. 2. Absence of complete correlation between the clinical results observed and the cinegammagraphic developments 3. Similarity of the results independent of the initial localization 4. Establishment of a 6-month median survival period, with ten patients at present in a state of apparently complete remission, 180-506 days after beginning of the treatment.

Adult↗